GlassScriptPhysician profile
Keegan Cathrene Collins
NPI 1407331747
$2,171.07
in general payments reported to CMS, 2019-2025
12 companies · $671 in 2025
The $671 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $287 · 2023: $916 · 2024: $143 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $378.80 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $248.80 | 2025 | Zerbaxa |
| Abbvie INC. | $238.49 | 2023-2025 | |
| Astellas Pharma US INC | $211.11 | 2023 | Cresemba |
| Impulse Dynamics (USA) INC. | $175.78 | 2023 | Optimizer |
| Boston Scientific Corporation | $174.19 | 2025 | Farapulse |
| Sanofi-Aventis U.S. LLC | $171.00 | 2022 | |
| Sobi, INC | $125.00 | 2024 | |
| Fresenius Kabi USA, LLC | $122.54 | 2025 | Smoflipid |
| Daiichi Sankyo INC. | $115.22 | 2023 | Injectafer |
| Mallinckrodt Hospital Products INC. | $107.73 | 2025 | Terlivaz |
| Astrazeneca Pharmaceuticals LP | $102.41 | 2023 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keegan Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.